14th National Clinical Pharmacology Workshop, Giens, France, 4-6 October 1998: How to improve drug development and utilization in children

Therapie

Volumn 54, Issue 4, 1999, Pages 423-432

  Pons, G ^a   Lassale, C ^b   Eschwege, E ^c   Amédée Manesme, Olivier ^j   Aubier, Françoise ^j   Autret Leca, Elisabeth ^j   Bellissant, Eric ^j   Brion, Françoise ^j   Chaumet Riffaud, Philippe ^j   Courcier, Soizic ^j   Eschwege, Evelyne ^j   Garreau, Martine ^j   Hoog Labouret, Nathalie ^d   Ichou, Françoise ^e   Jacqz Aigrain, Evelyne ^j   Leperlier, Cyrille ^j   Pletan, Yannick ^f   Sallière, Dominique ^g   Spriet, Alain ^j   O'Quigley, John ^j   Saint Raymond, Agnès ^d   Sarkozy, François ^h   Serreau, Raphael ^j   Vassal, Gilles ⁱ   Vasmant, Daniel ^h   Vauzelle Kervroëdan, Françoise ^j   Weil Oliver, Catherine ^j   more..

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d Agence du Medicament   (France)

^e Laboratoire Roussel Diamant   (France)

^f PFIZER INC   (United States)

^g SANOFI   (France)

^h Laboratoires Hoechst Marion R   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j NONE

more..

Author keywords

Children; Drug evaluation; Drug utilization; Drugs

Indexed keywords

CHILD; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; PEDIATRICS; PRESCRIPTION; PRIORITY JOURNAL; AGE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG EFFECT; ECONOMICS; EUROPE; FINANCIAL MANAGEMENT; GROWTH; HEALTH CARE ORGANIZATION; HUMAN; METHODOLOGY; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; REVIEW; RISK; SAFETY; STANDARD; STATISTICS; UNITED STATES;

DRUG; NON PRESCRIPTION DRUG;

AGE FACTORS; CHILD; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION; DRUG UTILIZATION; DRUGS, NON-PRESCRIPTION; EUROPE; GROWTH; HUMANS; MARKETING OF HEALTH SERVICES; MULTICENTER STUDIES; NATIONAL INSTITUTES OF HEALTH (U.S.); PATIENT EDUCATION; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; RISK; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0033154837     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Autret E, Vasmant D et les membres de la Table Ronde n°4 de Giens 10. Détermination de la posologie des médicaments en pédiatrie. Therapie 1995; 50: 381-386.
2. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Department of Health and Human Services-Food and Drug Administration, Federal Register, 2 December, 1998; 63 (231): 66632-66672.
3. Note for Guidance on Clinical Investigation of Medicinal Products in Children. Committee for Proprietary Medicinal Products (CPMP). The European Agency for the Evaluation of Medicinal Products, September 1997.
4. Burtin P, Jacqz-Aigrain E, Girard P et al. Population kinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56: 615-625.
5. O'Guigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
6. Whitehead J. The design and analysis of sequential clinical trials, 2nd edn Chichester: Ellis Horwood, 1992.
7. Bellissant E, Duhamel JF, Guillot M et al. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clin Pharmacol Ther 1997; 61: 377-384.
8. Pein F, Vassal G, Sakiroglu C et al. Pediatric aspects of anthracycline cardiotoxicity and practical implications for prevention. Arch Pediatr 1995; 2: 988-999.
9. Aubier F, Patte C, De Vathaire F et al. Male fertility after chemotherapy during childhood. Ann Endocrinol 1995; 56: 141-142.
10. Teinturier C, Hartmann O, Valteau-Couanet D et al. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 1998; 22: 989-994.